Nadroparin
- Generic Name
- Nadroparin
- Brand Names
- Fraxiparine
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 1K5KDI46KZ
- Background
Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactiv...
- Indication
Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.
- Associated Conditions
- Clotting, Deep Vein Thrombosis, Pulmonary Embolism, Unstable Angina Pectoris, Venous Thromboembolism, Non-q wave myocardial infarction, Thromboembolic phenomena
- Associated Therapies
- -
Heparin for Pregnant Women With Thrombophilia
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2009-11-25
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 300
- Registration Number
- NCT01019655
- Locations
- 🇦🇹
Department of Obstetrics and Gynecology, Vienna, Austria
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
- Conditions
- Interventions
- First Posted Date
- 2009-08-04
- Last Posted Date
- 2012-02-01
- Lead Sponsor
- Italfarmaco
- Target Recruit Count
- 1166
- Registration Number
- NCT00951574
- Locations
- 🇮🇹
Salvatore Maugeri Foundation, Pavia, Italy
🇮🇹Hematology and Oncology Department, Piacenza, Italy
🇮🇹Medical Oncology Department Regina Elena Institute, Roma, Italy
Prophylaxis of Thromboembolic Complications Trial: Thromboprophylaxis Needed in Below Knee Plaster Cast Immobilization for Ankle and Foot Fractures
- Conditions
- Interventions
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Red Cross Hospital Beverwijk
- Target Recruit Count
- 669
- Registration Number
- NCT00881088
- Locations
- 🇳🇱
Medical Center Alkmaar, Alkmaar, North Holland, Netherlands
🇳🇱University Medical Center Nijmegen, Nijmegen, Gelderland, Netherlands
🇳🇱Red Cross Hospital, Beverwijk, N-Holland, Netherlands
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1351
- Registration Number
- NCT00843492
- Locations
- 🇪🇸
GSK Investigational Site, Vigo/Pontevedra, Spain
Nadroparin for the Initial Treatment of Pulmonary Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2008-11-24
- Lead Sponsor
- Beijing Chao Yang Hospital
- Target Recruit Count
- 274
- Registration Number
- NCT00796692
- Locations
- 🇨🇳
The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳The Affiliated Hospital of Medical College Jining, Jining, Shandong, China
🇨🇳The Affiliated Hospital of Shenyang Medical University, Shenyang, Liaoning, China
Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 503
- Registration Number
- NCT00312013
- Locations
- 🇸🇮
GSK Investigational Site, Ljubljana, Slovenia
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
- Conditions
- First Posted Date
- 2006-03-16
- Last Posted Date
- 2006-03-16
- Lead Sponsor
- University Hospital, Geneva
- Registration Number
- NCT00303407
- Locations
- 🇨🇭
Center of Continuous Care, chemin de la Savonnière, Collonge-Bellerive (Geneva), Geneva, Switzerland
Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Onze Lieve Vrouwe Gasthuis
- Target Recruit Count
- 215
- Registration Number
- NCT00286273
- Locations
- 🇳🇱
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.